遠大醫藥(00512.HK):STC3141澳洲及比利時臨床試驗完成患者入組給藥
遠大醫藥(00512.HK)公布,附屬公司 Grand Medical Pty Ltd.開發的重症抗感染創新藥物STC3141,在澳洲和比利時開展的用於治療膿毒症的Ib期臨床試驗,近日已完成全部患者入組,並順利完成受試患者72小時的持續靜脈給藥,臨床研究報告預計將在未來四個月內完成。
STC3141作為遠大醫藥擁有全球權益的重磅產品,已在全球範圍內12個國家或地區進行專利佈局。
此外,集團重症抗感染領域的另一款口服小分子抗COVID-19的3CL蛋白(酉每)抑制劑GS221,也在中國順利開展臨床研究,目前已經完成的臨床試驗結果顯示受試者用藥後的安全性和耐受性良好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.